期刊
KIDNEY INTERNATIONAL
卷 79, 期 4, 页码 385-392出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2010.389
关键词
clinical trial; hypercalciuria; kidney disease: improving global outcomes; kidney stones; pathophysiology of renal disease and progression
资金
- National Institutes of Health [DK20543, DK081523, DK081432]
- O'Brien Center of Kidney Research [DK079328]
- Charles and Jane Pak Center of Mineral Metabolism
- Simmons Family Foundation
Urolithiasis is a worldwide problem with significant health and economic burdens. Medical therapy that alters the course of stone disease has enormous medical and financial impact. Urolithiasis is a final manifestation of a broad range of etiologies and pathogenesis. The modest progress in understanding the pathophysiology has hampered successful development of targeted therapy. Current regimens are based mostly on rational alteration of urinary biochemistry and physical chemistry to lower the risk of precipitation. In terms of pharmacotherapy, there are drugs to successfully improve hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria. These agents have been proven to be effective in randomized controlled trials in improving urinary biochemical and physicochemical risk factors, as well as clinical outcomes. Although our current regimens have clearly improved the management and lives of stone formers, there are still clearly identifiable immense voids in the knowledge of pathophysiology of stone disease that can be filled with combined basic science and clinical studies. Kidney International (2011) 79, 385-392; doi:10.1038/ki.2010.389; published online 6 October 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据